GLP‐1 agonists for obesity and type 2 diabetes in children: Systematic review and meta‐analysis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Summary: Pharmacological options for management of obesity and type 2 diabetes mellitus (T2DM) in children are limited. We aimed to synthesize published randomized controlled trial (RCT) evidence on the efficacy of glucagon‐like peptide‐1 (GLP‐1) agonists in T2DM, pre‐diabetes, and obesity in children aged <18 years. Inclusion criteria were RCTs of any GLP‐1 agonist, solely or in conjunction with other drugs, for the treatment of obesity, pre‐diabetes, and/or T2DM in children aged <18 years old. Nine studies met the inclusion criteria (two for T2DM, one for pre‐diabetes, and six for obesity without diabetes). In total, 286 children were allocated to GLP‐1 agonist therapy. Compared with controls, GLP‐1 agonist therapy reduced HbA1c by −0.30% (95% confidence interval [CI] −0.57, −0.04) with a larger effect in children with (pre‐)diabetes (−0.72%; 95% CI −1.17, −0.28; three studies) than in children with obesity (−0.08%; 95% CI −0.13, −0.02; four studies). Conversely, GLP‐1 agonist therapy reduced body weight more in children with obesity (−2.74 kg; 95% CI −3.77, −1.70; six studies) than in children with T2DM (−0.97 kg; 95% CI −2.01, 0.08; two studies). Adverse effects included gastrointestinal symptoms and minor hypoglycemic episodes, but not severe hypoglycemia. GLP‐1 agonists are efficacious in treating children with obesity and/or T2DM. Effect sizes are comparable with those reported in adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“Furthermore, GLP-1 delays gastric emptying, promotes satiety, and reduces food intake,(13) potentially leading to weight loss.(11,14,15) In adults, meta-analyses of randomized controlled trials (RCTs) of GLP-1 agonists in patients with T2DM and/or obesity have shown benefits on glycemic control and weight loss.”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916038 · Cited by 723 · cited 1×
“63).(24) Hence, our findings are reassuring in showing detectable glycemic benefits of GLP-1 agonists in children with obesity without diabetes, as well as in those with (pre-)diabetes.”
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394 · cited 1×
“6 kg (depending on the drug regimen).(21) Unlike some of those reviews in adults, in children, we found little or no contribution of treatment duration to study-level differences in treatment effect, although our analysis was limited by the small number of studies in children.”
BackgroundEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Lakshman, R., Elks, C. E., & Ong, K. K. (2012) · Circulation · doi:10.1161/circulationaha.111.047738 · Cited by 318
Self-citation
Research works printed but not linked: 19
- 10.1016/j.mayocp.2016.09.017 · DOI · Paper page
- 10.1111/ijpo.12495 · DOI · Paper page
- 10.1038/oby.2011.337 · DOI · Paper page
- 10.1089/dia.2013.0366 · DOI · Paper page
- 10.2337/dc18-0244 · DOI · Paper page
- 10.1016/S2352-4642(19)30236-6 · DOI
- 10.1056/NEJMoa1903822 · DOI · Paper page
- 10.1152/ajpendo.00639.2009 · DOI · Paper page
- 10.1016/j.ijcard.2016.06.028 · DOI
- 10.1016/j.jdiacomp.2016.08.018 · DOI
- 10.1007/s00592-017-1054-2 · DOI
- 10.3892/etm.2017.4129 · DOI
- 10.1016/j.jpeds.2016.10.076 · DOI · Paper page
- 10.1001/jamapediatrics.2013.1045 · DOI · Paper page
- Weghuber D, 2020, A 6‐month randomized, double‐blind, placebo‐controlled trial of weekly exenatide in adolescents with obesity, Pediatr Obes, e12624, 10.1111/ijpo.12624 · DOI · Paper page
- 10.5709/acp-0133-x · DOI · Paper page
- 10.18637/jss.v036.i03 · DOI · Paper page
- 10.1089/dia.2014.0188 · DOI · Paper page
- 10.1900/RDS.2014.11.202 · doi:10.1900/rds.2014.11.202
Cited by
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Ma, C.-X., Ma, X.-N., Guan, C.-H., Li, Y.-D., Mauricio, D., & Fu, S.-B. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01516-6 · Cited by 464
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125
Perez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29
“Similar heterogeneous treatment responses to GLP1RAs have been reported in other patient populations.(16) Determining why certain subjects show a treatment response could lead to the identification of biomarkers to guide therapy and predict treatment response.”
ResultThe efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis
Yugar, L. B. T., Sedenho-Prado, L. G., da Silva Ferreira, I. M. C., Silva, C. A. M., Sposito, A. C., & Cercato, C. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01337-5 · Cited by 23
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
“Notably, evidence suggests that these effects may be even more pronounced in overweight and obese individuals without T2DM [52], and studies support their safety and efficacy in pediatric populations as well [53,54].”
Metadata
- Authors
- Chadda, K. R., Cheng, T. S., & Ong, K. K.
- Venue
- Obesity Reviews
- Publisher
- Wiley
- Published
- 2020-12-22
- Volume
- 22
- Issue
- 6
- Pages
- e13177-e13177
- ISSN
- 1467-7881 (ISSN-L)
- 1467-789X
- OpenAlex
- W3113772690
- Cited by
- 103
- References
- 17
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Medical Research Council Canada (MC_UU_12015/2)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.